Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to dominate it over the coming year.

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and conducted by University of Chicago researchers,

In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.

Hims & Hers Health Inc.’s shares rose Tuesday after it said it was broadening its weight-loss offerings, adding access to brand name shots like Zepbound after previously focusing on cheaper versions made by compounding pharmacies.